SFX by Ex Libris Inc.

Title:	Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement
Source:	Cancer [0008-543X] Erinjeri, Joseph yr:2010

Basic

Full text

Full text available via Wiley Online Library Free Backfiles

Year:

Volume:

Issue:

Start Page:

Full text available via Wiley Online Library STM 2011

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Bose, D. "Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care." The lancet oncology 11.4 (2010): 373-382.
description	2.	Sharma, K. "Bevacizumab and wound-healing complications: Mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon." Annals of plastic surgery 71.4 (2012): 1-440.
description	3.	Stone, Rebecca L. "Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer." The lancet oncology 11.5 (2010): 465-75.
description	4.	Guillou, Pierre J J. "Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial." Lancet, The 365.9472 (2005): 1718-26.
description	5.	Kim, Eun C. "Bevacizumab eye drops delay corneal epithelial wound healing and increase the stromal response to epithelial injury in rats." Clinical & experimental ophthalmology (2013): 694-701.
description	6.	Bouzid, K. "Therapeutic monoclonal antibodies in oncology \| Anticorps monoclonaux thérapeutiques en cancérologie." Pathologie et biologie 60.4 (2012): 223-228.
description	7.	Price, Timothy J. ""Watchful waiting" for metastatic colorectal cancer, antediluvian or an option to be considered again?" Asia-Pacific journal of clinical oncology (2012): 10-13.
description	8.	LeBlanc, Amanda J J. "Age impairs Flk-1 signaling and NO-mediated vasodilation in coronary arterioles." American journal of physiology. Heart and circulatory physiology 295.6 (2008): -8.
description	9.	Eng, C. "The Evolving Role of Monoclonal Antibodies in Colorectal Cancer: Early Presumptions and Impact on Clinical Trial Development." The oncologist 15.1 (2010): 73-84.
description	10.	Achen, M G G. "The vascular endothelial growth factor family; proteins which guide the development of the vasculature." International journal of experimental pathology 79.5 (1998): 255-65.
description	11.	Holash, J. "Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF." Science 284.5422 (1999): 1994-1998.
description	12.	Jayne, P. J. G. "Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer." The British journal of surgery 97.11 (2010): 1638-1645.
description	13.	Veldkamp, H Jaap A. "Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial." The lancet oncology 6.7 (2005): 477-84.
description	14.	Lacy, J. "Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial." Lancet, The 359.9325 (2002): 2224-9.
description	15.	Kim, Sung-Bum H. "Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial." The lancet oncology 11.7 (2010): 637-645.
description	16.	Smith, Julia M G. "Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group." Journal of clinical oncology 25.21 (2007): 3061-8.
description	17.	Nout, V T H B M A. "Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial." The Lancet 375.9717 (2010): 816-823.
description	18.	Mountzios, G. "Bevacizumab and micrometastases: Revisiting the preclinical and clinical rollercoaster." Pharmacology & therapeutics 141.2 (2013): 117-124.
description	19.	Biaoxue, R. "Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer.(Research)(Report)." World journal of surgical oncology 10 (2012): 170-.
description	20.	Curigliano, G. "Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines." Annals of oncology 23.SUPPL. 7 (2012): -66.